Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer

Background Amrubicin and cisplatin is one of the active regimens used to treat patients with extensive-disease (ED)-small cell lung cancer (SCLC), whereas combined therapy involving chemotherapy and concurrent thoracic radiotherapy is the standard treatment for limited-disease (LD)-SCLC. Purpose Thi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2019-11, Vol.84 (5), p.1059-1064
Hauptverfasser:	Shimada, Midori, Yamaguchi, Hiroyuki, Fukuda, Minoru, Tomono, Hiromi, Honda, Noritaka, Dotsu, Yosuke, Taniguchi, Hirokazu, Gyotoku, Hiroshi, Senju, Hiroaki, Takemoto, Shinnosuke, Ikeda, Takaya, Nakatomi, Katsumi, Nakamura, Yoichi, Nagashima, Seiji, Yamazaki, Takuya, Mukae, Hiroshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anthracyclines - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Cancer Research Chemotherapy Cisplatin Cisplatin - administration & dosage Disease control Dose-Response Relationship, Drug Female Humans Leukopenia Lung cancer Lung diseases Lung Neoplasms - drug therapy Lung Neoplasms - radiotherapy Male Maximum Tolerated Dose Medical treatment Medicine Medicine & Public Health Middle Aged Neutropenia Oncology Original Article Pharmacology/Toxicology Progression-Free Survival Radiation therapy Small cell lung carcinoma Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - radiotherapy Survival Survival Rate Thorax Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!